Retrospective Evaluation of Demographic and Clinical Features of Gastrointestinal Stromal Tumors

Öz

This study aimed to retrospectively examine the demographic, clinical, and pathological characteristics; prognostic risk factors; treatments administered; clinical course; and survival times of patients diagnosed with gastrointestinal stromal tumors (GIST) and treated and followed up at Department of Medical Oncology at the Bursa Uludağ University Faculty of Medicine in Bursa. Medical records of 54 patients diagnosed with GIST between 2002 and 2017 were reviewed retrospectively through the hospital record system. The mean age was 56.15 ± 10.68 years, and the disease was more prevalent in men (n = 34, 63.0%). The most common primary tumor site was the small intestine (n=22, 40.7%), followed by the stomach (n=19, 35.2%). The most common symptom was abdominal pain (n=40, 74.1%). Liver metastasis was the most common (n=12, 54.5%). CD117 (C-KIT) was the most common immunohistochemical staining marker (n=51, 94.4%). Most patients had high-risk disease. Patients who underwent curative surgery had longer survival times. While a high mitotic index and lymph node metastasis were associated with progression, tumor size, location, and stage were not associated with progression. This study illuminates the demographic and clinical characteristics of patients diagnosed with GIST.

Anahtar Kelimeler

• Gastrointestinal stromal tumor
• Imatinib
• Sunitinib
• Survival

Gastrointestinal Stromal Tümörlerin Demografik ve Klinik Özelliklerinin Retrospektif Değerlendirilmesi

Öz

Bu çalışma, Bursa Uludağ Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Bilim Dalı'nda gastrointestinal stromal tümör (GIST) tanısı konulan, tedavi edilen ve takip edilen hastaların demografik, klinik ve patolojik özelliklerini, prognostik risk faktörlerini, uygulanan tedavileri, klinik seyrini ve sağkalım sürelerini retrospektif olarak incelemek amacıyla yapılmıştır. 2002-2017 yılları arasında GIST tanısı konulan 54 hastanın tıbbi kayıtları, hastane kayıt sistemi aracılığıyla retrospektif olarak incelenmiştir. Ortalama yaş 56,15 ± 10,68 idi ve hastalık erkeklerde daha yaygındı (n=34, %63,0). En yaygın tümör yerleşim bölgesi ince bağırsak (n=22, %40,7) idi, bunu mide (n=19, %35,2) izliyordu. En sık görülen semptom karın ağrısıydı (n=40, %74,1). Karaciğer metastazı en sık görülen metastaz türüydü (n=12, %54,5). CD117 (C-KIT) en sık görülen immünohistokimyasal boyama markeriydi (n=51, %94,4). Çoğu hasta yüksek riskli hastalığa sahipti. Küratif cerrahi geçiren hastaların hayatta kalma süreleri daha uzundu. Yüksek mitotik indeks ve lenf nodu metastazı ilerleme ile ilişkiliyken, tümör boyutu, yeri ve evresi ilerleme ile ilişkili değildi. Bu çalışma, GIST tanısı konulan hastaların demografik ve klinik özelliklerini aydınlatmaktadır.

Anahtar Kelimeler

• Gastrointestinal stromal tümör
• İmatinib
• Sunitinib
• Sağkalım

Kaynakça

1. 1. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130(10):1466-1478.
2. 2. Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet. 2013;382(9896):973-983.
3. 3. Kindblom L-G, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152(5):1259-1269.
4. 4. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577-580.
5. 5. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299(5607):708-710.
6. 6. Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39-46.
7. 7. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol. 1999;30(10):1213-1220.
8. 8. Casali P, Abecassis N, Bauer S, et al. Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv68-iv78.

9. 9. Demetri GD, Von Mehren M, Antonescu CR, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010;8(Suppl_2):S-1-S-41.
10. 10. Miettinen M, Monihan JM, Sarlomo-Rikala M, et al. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol. 1999;23(9):1109-1118.
11. 11. Nilsson B, Bümming P, Meis‐Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era: a population‐based study in western Sweden. Cancer. 2005;103(4):821-829.
12. 12. Sepe PS, Brugge WR. A guide for the diagnosis and management of gastrointestinal stromal cell tumors. Nat Rev Gastroenterol Hepatol. 2009;6(6):363-371.
13. 13. Caterino S, Lorenzon L, Petrucciani N, et al. Gastrointestinal stromal tumors: correlation between symptoms at presentation, tumor location and prognostic factors in 47 consecutive patients. World J Surg Oncol. 2011;9(1):13.
14. 14. Sandrasegaran K, Rajesh A, Rushing DA, Rydberg J, Akisik FM, Henley JD. Gastrointestinal stromal tumors: CT and MRI findings. Eur Radiol. 2005;15(7):1407-1414.
15. 15. King DM. The radiology of gastrointestinal stromal tumours (GIST). Cancer Imaging. 2005;5(1):150-156.
16. 16. Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol. 2006;30(4):477-489.
17. 17. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006 May;23(2):70-83.
18. 18. Joensuu H, DeMatteo RP. The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy. Annu Rev Med. 2012;63(1):247-258.
19. 19. Blay J-Y, Kang Y-K, Nishida T, von Mehren M. Gastrointestinal stromal tumours. Nat Rev Dis Primers. 2021;7(1):22.
20. 20. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329-1338.
21. 21. Demetri GD, Reichardt P, Kang Y-K, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295-302.
22. 22. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-656.
23. 23. Gold JS, DeMatteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg. 2006;244(2):176-184.
24. 24. Duffaud F, Blay J-Y. Gastrointestinal stromal tumors: biology and treatment. Oncology. 2003;65(3):187-197.
25. 25. van der Zwan SM, DeMatteo RP. Gastrointestinal stromal tumor: 5 years later. Cancer. 2005;104(9):1781-1788.
26. 26. Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer. 2002;38:S39-S51.
27. 27. D'amato G, Steinert DM, McAuliffe JC, Trent JC. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control. 2005;12(1):44-56.
28. 28. Von Mehren M, Randall RL, Benjamin RS, et al. Soft tissue sarcoma, version 2.2014. J Natl Compr Canc Netw. 2014;12(4):473-483.
29. 29. Güller U, Tarantino I, Cerny T, Schmied BM, Warschkow R. Population-based SEER trend analysis of overall and cancer-specific survival in 5138 patients with gastrointestinal stromal tumor. BMC Cancer. 2015;15(1):557.
30. 30. Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol. 2004;11(5):465-475.
31. 31. DeMatteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9669):1097-1104.
32. 32. Von Mehren M, Benjamin RS, Bui MM, et al. Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012;10(8):951-960.
33. 33. Seker M, Sevinc A, Yildiz R, et al. Prognostic factors in gastrointestinal stromal tumors: multicenter experience of 333 cases from Turkey. Hepatogastroenterology. 2012;60(124):768-775.